Paraneoplastic Syndrome Management

Introduction to Paraneoplastic SIADH

• Paraneoplastic syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a condition where a tumor, often small cell lung cancer (SCLC), produces antidiuretic hormone (ADH), leading to hyponatremia, as noted by the American College of Chest Physicians and the National Comprehensive Cancer Network 1, 2
• The American College of Chest Physicians recommends diagnosing paraneoplastic SIADH based on hyponatremia (serum sodium <134 mEq/L), hypoosmolality (plasma osmolality <275 mOsm/kg), inappropriately high urine osmolality (>500 mOsm/kg), and inappropriately high urinary sodium concentration (>20 mEq/L) in the absence of edema or volume depletion, with normal adrenal and thyroid function 1

Diagnosis and Characteristics

• Diagnostic criteria for SIADH include hyponatremia (serum sodium <134 mEq/L), hypoosmolality (plasma osmolality <275 mOsm/kg), inappropriately high urine osmolality (>500 mOsm/kg), and inappropriately high urinary sodium concentration (>20 mEq/L), with normal adrenal and thyroid function, as outlined by the American College of Chest Physicians and the National Comprehensive Cancer Network 1, 3, 4, 5
• Serum studies, including sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, serum osmolality, liver function tests, and calcium, are essential for diagnosing SIADH, according to the American College of Chest Physicians 1
• Urine studies, such as urine sodium and urine osmolality, are also crucial in diagnosing SIADH, as stated by the American Thoracic Society 1
• Chest imaging, such as CT scan, is important to rule out small cell lung cancer, which accounts for 10-45% of SIADH cases, as reported by the American College of Chest Physicians 1
• The key difference between SIADH and Cerebral Salt Wasting (CSW) is volume status, with SIADH being euvolemic and CSW being hypovolemic, as shown in the following table:

6

Treatment

• The National Comprehensive Cancer Network recommends primary treatment of the underlying malignancy, combined with fluid restriction and vasopressin receptor antagonists for symptomatic hyponatremia, as the most effective approach to managing paraneoplastic SIADH in patients with SCLC 1, 2
• Initial treatment steps for SIADH include discontinuation of implicated medications, if possible, fluid restriction (1,000-1,500 mL/day), and adequate oral salt intake, as recommended by the American College of Physicians and the Annals of Oncology guidelines 3, 4, 5
• Tolvaptan (vasopressin receptor antagonist) can be used, with a starting dose of 15 mg once daily, titrated to 30 mg, then 60 mg once daily as needed, with close monitoring of serum sodium, as recommended by the American Heart Association 7
• Demeclocycline can be used to induce negative free-water balance if fluid restriction is not tolerated, and urea can be effective for rapid correction of symptomatic hyponatremia in SIADH 5
• Correction of serum sodium levels should not exceed 8-10 mmol/L per day to avoid osmotic demyelination syndrome, as recommended by the Journal of Hepatology guidelines and the American College of Physicians 7, 8, 5

Management of Severe Symptomatic Cases

• For severe symptomatic cases, transfer to ICU, monitor sodium every 2 hours, administer 3% hypertonic saline, calculate sodium deficit, and correct 6 mEq/L over 6 hours or until severe symptoms resolve, without exceeding correction of 8 mmol/L over 24 hours to avoid osmotic demyelination syndrome, as advised by the Neurocritical Care Society 6
• Once severe symptoms resolve, transition to protocol for mild symptoms, including fluid restriction (1,000-1,500 mL/day), oral sodium supplementation, high protein diet, and daily weights, as recommended by the American Heart Association 6

Monitoring and Prevention of Complications

• Daily weights, regular electrolyte monitoring, and monitoring for signs of rapid correction (risk of osmotic demyelination) are crucial, as emphasized by the Endocrine Society 9
• Overly rapid correction of sodium (>8 mmol/L/24h) can lead to osmotic demyelination syndrome, emphasizing the need for careful monitoring and gradual correction 6
• Misdiagnosing CSW as SIADH can worsen outcomes as treatment approaches are opposite, highlighting the importance of accurate diagnosis 6
• Assess pituitary function in patients with meningiomas near the pituitary gland, as recommended by the European Society of Endocrinology 9

Differential Diagnosis

• The National Comprehensive Cancer Network suggests differentiating SIADH from other causes of hyponatremia in cancer patients, including chemotherapy-induced (cisplatin, opiates), volume depletion, adrenal insufficiency, and hypothyroidism 2, 10
• Other malignancies, such as head and neck cancers and extrapulmonary small cell carcinomas, have been reported to be associated with SIADH, as well as paraneoplastic encephalomyelitis and chemotherapeutic agents like cisplatin 2, 3
• CNS disorders, such as stroke, hemorrhage, trauma, and infection, can also cause SIADH, as well as pulmonary diseases, including pneumonia, tuberculosis, asthma, and COPD 1
• Medications, such as antidepressants, antipsychotics, anticonvulsants, diuretics, NSAIDs, opioids, and chemotherapeutic agents, can induce SIADH, highlighting the importance of medication review 1, 11, 12